Project Leader
Ono Pharmaceutical Co., Ltd. · Ono PharmaceuticalCo., Ltd. · Ono Pharma USA Inc
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Project Leader as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07832747 · A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCTOno Pharmaceutical Co., Ltd. · not yet recruiting · Tenosynovial Giant Cell Tumor · study director
- Ph2NCT07823790 · ONO-4915 in Patients With Primary Sjogren's DiseaseOno Pharmaceutical Co., Ltd. · not yet recruiting · Sjogren's Disease · study director
- Ph1NCT07787208 · A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid TumorsOno Pharmaceutical Co., Ltd. · recruiting · Solid Tumors · study director
- Ph1NCT07749768 · A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative ColitisOno Pharmaceutical Co., Ltd. · recruiting · Ulcerative Colitis (UC) · study director
- Ph1/Ph2NCT07734116 · A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.Ono Pharmaceutical Co., Ltd. · recruiting · Pediatric Malignant Solid Tumor and Epithelioid Sarcoma · study director
- Ph1NCT07619157 · A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes MellitusOno Pharmaceutical Co., Ltd. · recruiting · Type2 Diabetes Mellitus, Chronic Kidney Disease · study director
- Ph1NCT07618377 · Study of DCC-2618 in Patients With GIST After at Least 3 Prior TreatmentsOno Pharmaceutical Co., Ltd. · recruiting · Gastrointestinal Stromal Tumors · study director
- Ph3NCT07594158 · A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year OldsOno Pharmaceutical Co., Ltd. · recruiting · Partial Epilepsy · study director
- Ph1NCT07198087 · A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsOno Pharmaceutical Co., Ltd. · completed · Primary Central Nervous System Lymphoma (PCNSL) · study director
- Ph2NCT06948448 · A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal CancerOno Pharmaceutical Co., Ltd. · recruiting · Colorectal Cancer · study director
- Ph2NCT06936943 · ONO-4538 Study in Patients With Richter's TransformationOno Pharmaceutical Co., Ltd. · recruiting · Richter's Transformation · study director
- Ph2NCT06881836 · A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's DiseaseOno Pharmaceutical Co., Ltd. · completed · Alzheimer Disease · study director
- Ph1NCT06816108 · A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid TumorsOno Pharmaceutical Co., Ltd. · active not recruiting · Solid Tumor, NSCLC · study director
- Ph2NCT06805565 · A Study of ONO-1110 in Patients With Social Anxiety DisorderOno Pharmaceutical Co., Ltd. · completed · Social Anxiety Disorder (SAD) · study director
- Ph2NCT06803823 · A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease DementiaOno Pharmaceutical Co., Ltd. · recruiting · Agitation Associated With Alzheimer's Disease Dementia · study director
- Ph2NCT06792136 · A Study of ONO-1110 in Patients With Major Depressive DisorderOno Pharmaceutical Co., Ltd. · completed · Major Depressive Disorder (MDD · study director
- Ph2NCT06752603 · A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial CystitisOno Pharmaceutical Co., Ltd. · completed · Hunner Type Interstitial Cystitis · study director
- Ph2NCT06752590 · A Clinical Study of ONO-1110 in Patients With FibromyalgiaOno Pharmaceutical Co., Ltd. · completed · Fibromyalgia · study director
- Ph2NCT06708416 · A Study of ONO-1110 in Patients With Postherpetic NeuralgiaOno Pharmaceutical Co., Ltd. · completed · Postherpetic Neuralgia · study director
- Ph3NCT06696716 · ONO-4059 Study in Patients With Steroid-resistant PemphigusOno Pharmaceutical Co., Ltd. · active not recruiting · Pemphigus, Steroid-resistant Pemphigus · study director
- Ph2NCT06622941 · Study to ONO-4538 in Patients With Rhabdoid TumorOno Pharmaceutical Co., Ltd. · recruiting · Rhabdoid Tumor · study director
- Ph1NCT06622226 · A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaOno Pharmaceutical Co., Ltd. · terminated · Non Hodgkin Lymphoma · study director
- Ph2NCT06590896 · Safety of Cenobamate in Japanese Subjects With Partial Onset SeizuresOno Pharmaceutical Co., Ltd. · recruiting · Epilepsies, Partial · study director
- Ph3NCT06579573 · ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.Ono Pharmaceutical Co., Ltd. · recruiting · Epilepsy, Generalized · study director
- Ph1NCT06570031 · ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerOno Pharmaceutical Co., Ltd. · completed · Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer · study director
- Ph1NCT06548217 · A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid TumorsOno Pharmaceutical Co., Ltd. · active not recruiting · Advanced or Metastatic Solid Tumors · study director
- Ph1NCT06547385 · Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal CancerOno Pharmaceutical Co., Ltd. · active not recruiting · Colorectal Cancer · study director
- Ph1NCT06547528 · A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLLOno Pharmaceutical Co., Ltd. · active not recruiting · Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · study director
- Ph1NCT06541665 · Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSLOno Pharmaceutical Co., Ltd. · active not recruiting · Primary Central Nervous System Lymphoma · study director
- Ph1NCT06542731 · An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerOno Pharmaceutical Co., Ltd. · completed · Non-small Cell Lung Cancer · study director
- Ph1NCT06540261 · The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal CancerOno Pharmaceutical Co., Ltd. · active not recruiting · Unresectable Colorectal Cancer · study director
- Ph1NCT06538207 · An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic CancerOno Pharmaceutical Co., Ltd. · completed · Metastatic Pancreatic Cancer · study director
- Ph2NCT06538272 · Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly PaclitaxelOno Pharmaceutical Co., Ltd. · completed · CIPN - Chemotherapy-Induced Peripheral Neuropathy · study director
- Ph1NCT06535009 · Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid TumorsOno Pharmaceutical Co., Ltd. · terminated · Solid Tumor · study director
- Ph1NCT06532331 · A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic CancerOno Pharmaceutical Co., Ltd. · active not recruiting · Metastatic Pancreatic Cancer · study director
- Ph1NCT06532344 · An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic CancerOno Pharmaceutical Co., Ltd. · active not recruiting · Metastatic Pancreatic Cancer · study director
- Ph1NCT06525246 · Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerOno Pharmaceutical Co., Ltd. · completed · Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer · study director
- Ph2NCT06256328 · A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Ono Pharmaceutical Co., Ltd. · active not recruiting · Gastric Cancer · study director
- Ph2NCT05923866 · A Phase 2 Study of ONO-2808 in Patients With Multiple System AtrophyOno Pharmaceutical Co., Ltd. · active not recruiting · Multiple System Atrophy (MSA) · study director
- Ph1NCT05515406 · A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLLOno Pharmaceutical Co., Ltd. · terminated · Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell · study director
- Ph1NCT05507515 · A Phase 1 Study of ONO-2020 in Healthy ParticipantsOno Pharmaceutical Co., Ltd. · completed · Healthy Volunteers · study director
- Ph1NCT05332704 · Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685Ono Pharmaceutical Co., Ltd. · completed · Plaque Psoriasis · study director
- Ph3NCT05144854 · A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Ono Pharmaceutical Co., Ltd. · active not recruiting · Gastric Cancer · study director
- Ph1NCT05079282 · Study of ONO-4685 in Patients With Relapsed or Refractory T Cell LymphomaOno Pharmaceutical Co., Ltd. · active not recruiting · Relapsed or Refractory T Cell Lymphoma · study director
- Ph2NCT04947319 · Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)Ono Pharmaceutical Co., Ltd. · active not recruiting · Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma · study director
- Ph2NCT04566380 · ONO-4538 Phase II Rollover Study (ONO-4538-98)Ono Pharmaceutical Co., Ltd. · recruiting · Pan-tumor · study director
- Ph1NCT03730337 · Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsOno Pharmaceutical Co., Ltd. · completed · Advanced or Metastatic Solid Tumors · study director
- Ph1/Ph2NCT03176277 · A Study of ONO-7475 in Patients With Acute LeukemiasOno Pharmaceutical Co., Ltd. · terminated · Acute Leukemia, Myelodysplastic Syndromes · study director
- Ph1NCT03155061 · Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsOno Pharmaceutical Co., Ltd. · active not recruiting · Advanced or Metastatic Solid Tumors · study director
- Ph3NCT03006705 · Study of Adjuvant ONO-4538 With Resected Gastric CancerOno Pharmaceutical Co., Ltd. · completed · Gastric Cancer · study director
- Ph3NCT01789970 · Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back PainTeva Branded Pharmaceutical Products R&D, Inc. · completed · Low Back Pain · study director
- Ph3NCT01747629 · Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State PharmacokineticsTeva Branded Pharmaceutical Products R&D, Inc. · completed · Asthma · study director
- Ph3NCT01424813 · A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent AsthmaTeva Branded Pharmaceutical Products R&D, Inc. · completed · Asthma · study director
- N/ANCT01302587 · A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)Teva Branded Pharmaceutical Products R&D, Inc. · completed · Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema · study director
- Ph4NCT01248468 · Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of MigraineNovartis · completed · Pain, Migraine · study director
- Ph3NCT01218009 · A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed DosingTeva Branded Pharmaceutical Products R&D, Inc. · terminated · Asthma · study director
- Ph2NCT00335712 · Pilot Study of ONO-5129 in Patients With Type 2 Diabetes MellitusOno Pharma USA Inc · completed · Type 2 Diabetes Mellitus · study director
- Ph2/Ph3NCT00229177 · Study of ONO-2506 in Patients With Acute Ischemic StrokeOno Pharmaceutical Co., Ltd. · completed · Stroke · study director
- Ph4NCT00219375 · Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in JapanOno Pharmaceutical Co., Ltd. · completed · Acute Lung Injury, Systemic Inflammatory Response Syndrome · study director
- Ph3NCT00212719 · Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in JapanOno Pharmaceutical Co., Ltd. · completed · Involutional Osteoporosis · study director
- Ph2NCT00212706 · Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in JapanOno Pharmaceutical Co., Ltd. · completed · Overactive Bladder · study director
- Ph2NCT00212602 · ONO-7436 Phase II Study in JapanOno Pharmaceutical Co., Ltd. · completed · Malignant Tumor · study director
- Ph2NCT00212693 · Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in JapanOno Pharmaceutical Co., Ltd. · completed · Parkinson's Disease · study director
- Ph2NCT00212680 · Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in JapanOno Pharma USA Inc · completed · Postoperative Supraventricular Tachyarrythmia · study director
- Ph3NCT00212628 · Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in JapanOno Pharmaceutical Co., Ltd. · completed · Involutional Osteoporosis · study director
- Ph3NCT00212732 · Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in JapanOno Pharmaceutical Co., Ltd. · completed · Overactive Bladder · study director
- Ph3NCT00212667 · Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in JapanOno Pharmaceutical Co., Ltd. · completed · Involutional Osteoporosis · study director
- Ph2/Ph3NCT00212654 · Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in JapanOno Pharmaceutical Co., Ltd. · completed · Postoperative Supraventricular Tachyarrythmia · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in atypical teratoid rhabdoid tumour (at/rt).